このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CureVac バランスシートの健全性

財務の健全性基準チェック /46

CureVacの総株主資本は€446.9M 、総負債は€0.0で、負債比率は0%となります。総資産と総負債はそれぞれ€690.4Mと€243.5Mです。

主要情報

負債資本比率

€0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	€300.15m
エクイティ	€446.91m
負債合計	€243.52m
総資産	€690.43m

財務の健全性に関する最新情報

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29

Recent updates

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb 04

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27

CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates

Jan 11

財務状況分析

短期負債: CVACの短期資産 ( €377.9M ) が短期負債 ( €167.9M ) を超えています。

長期負債: CVACの短期資産 ( €377.9M ) が長期負債 ( €75.6M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: CVACは負債がありません。

負債の削減: CVAC負債比率が143.3%であった 5 年前と比べて負債がありません。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: CVACは、現在のフリーキャッシュフローに基づくと、キャッシュランウェイが 1 年未満です。

キャッシュランウェイの予測: CVACは、フリーキャッシュフローが毎年28.9 % の歴史的率で減少し続ける場合、キャッシュランウェイが 1 年未満になります。

CureVac バランスシートの健全性

財務の健全性 基準チェック /46

主要情報

財務の健全性に関する最新情報

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Recent updates

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 29%, EPS upgraded

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Consensus revenue estimates increase by 57%

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Consensus revenue estimates decrease by 42%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

Now 31% undervalued

CureVac N.V. Announces CEO Changes

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CureVac Announces Executive Changes

CureVac BV reports Q2 results

Consensus estimates of losses per share improve by 10%

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Insider notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 36%

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac: Wait For Concrete News Before Investing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Forecast breakeven moved forward to 2021

CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV

Co-Founder notifies of intention to sell stock

財務の健全性基準チェック /46